Refnot, lyophilizate 100000 units 5 pcs

REFNOT® has direct antitumor effects in vitro and in vivo on various tumor cell lines. In terms of the spectrum of cytotoxic and cytostatic action on tumor cells, the drug corresponds to human tumor necrosis factor α (TNF), but REFNOT® has more than 100 times lower total toxicity than TNF.

The mechanism of antitumor action of REFNOT® in vivo includes several pathways by which the drug destroys tumor or stops its growth:

The direct action of tumor necrosis factor-thymosin alpha-1 (TNF-T) on a target tumor cell through the appropriate receptors on its surface, resulting in cell apoptosis (cytotoxic action) or cell cycle arrest (cytostatic action);

– a cascade of chemical reactions including activation of the blood coagulation system and local inflammatory reactions caused by REFNOT®-activated endothelial cells and lymphocytes and leading to hemorrhagic tumor necrosis;

– blockage of angiogenesis, leading to reduction of new vascular infiltration of the rapidly growing tumor and, as a result, reduction of blood supply up to the necrosis of the tumor center;

p> – exposure of immune system cells whose cytotoxicity was found to be closely linked to the presence of TNF-T molecules on their surface or the process of maturation/activation of these cells is linked to a response to TNF-T.

Combinations of REFNOT® with α2- or γ-interferons have a synergistic cytotoxic effect. REFNOT® enhances antiviral activity of recombinant interferon gamma 100-1000 times (against vesicular stomatitis virus).

REFNOT® increases the effectiveness of chemopreparations: actinomycin D, cytarabine, doxorubicin against tumor cells with low sensitivity to them, eliminating this resistance. This allows REFNOT® to be considered as a modifier of antitumor action of chemical cytostatics in cases of multidrug resistance of tumor cells.

Indications

Breast cancer in complex therapy with chemotherapy.

Composition

Active ingredient:

Tumor necrosis factor-thymosin alpha-1 recombinant 100000 units;

Auxiliary substances:

Mannitol (mannitol);

sodium chloride;

Sodium phosphate dihydrate (sodium phosphate monosubstituted divalent);

dodecahydrate sodium phosphate (sodium phosphate displaced twice)

How to take, the dosage

To treat breast cancer in combination with chemotherapy the average daily dose of the drug is 200000 units. The drug is administered by injection on the day of chemotherapy (30 minutes) and for 4 days after chemotherapy once a day.

The contents of the bottle are dissolved in 1 ml of water for injection immediately before use.

Contraindications

Hypersensitivity to TNF-T or any other component of the drug; pregnancy and lactation.

Side effects

Individual hypersensitivity to the drug has been noted.

In some patients REFNOT® causes short-term (up to several hours) fever of 1-2 °C, chills.

The side effects are relieved by additional administration of indomethacin or ibuprofen, which do not affect the cytotoxic effects of the drug.